Bispecific antibody–drug conjugate (aka iza-bren; izalontamab brengitecan; BMS-986507) that binds EGFR and HER3 and delivers a topoisomerase I inhibitor payload (brengitecan) to induce DNA damage and tumor cell death.
Bispecific antibody–drug conjugate that binds EGFR and HER3 on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload (brengitecan) to induce DNA damage and apoptosis in EGFR/HER3-expressing cells.
NO
INDIRECT
BL-B01D1 binds EGFR/HER3 on tumor cells, is internalized, and releases a topoisomerase I inhibitor (brengitecan) that induces DNA damage and apoptosis. Topoisomerase I is the intracellular enzymatic payload target, not the surface antigen recognized by the drug; cells expressing only topoisomerase I are not selectively killed.
Autologous anti-CD19 CAR T-cell therapy with CD3ζ/CD28 costimulation used to treat relapsed/refractory B-cell lymphomas.
Autologous T cells are genetically engineered to express an anti‑CD19 chimeric antigen receptor with CD28 costimulation and CD3ζ signaling. Upon binding CD19 on malignant B cells, the CAR activates T-cell cytotoxicity, proliferation, and cytokine release, leading to targeted lysis of CD19-positive tumor cells.
YES
DIRECT
Anti-CD19 CAR T cells bind CD19 and, via CD3ζ/CD28 signaling, activate cytotoxic degranulation to kill CD19+ cells through perforin/granzyme–mediated apoptosis.
Autologous anti-CD19 CAR T-cell therapy with CD3ζ/4-1BB costimulation used for B-cell malignancies including DLBCL.
Autologous anti-CD19 CAR T cells incorporating CD3zeta signaling and a 4-1BB costimulatory domain; upon binding CD19 on B cells, they activate, expand, release cytotoxic mediators and cytokines, and kill malignant CD19+ B cells.
YES
DIRECT
Anti-CD19 CAR T cells bind CD19 and, via CD3ζ/4-1BB signaling, activate cytotoxic T-cell functions to kill CD19+ cells through perforin/granzyme release and Fas–FasL–mediated apoptosis.
Autologous anti-CD19 CAR T-cell therapy with CD3ζ/4-1BB costimulation; defined CD4/CD8 composition; used for large B-cell lymphoma.
Autologous T cells engineered to express a CD19-directed chimeric antigen receptor with CD3zeta signaling and 4-1BB costimulation. Upon binding CD19 on malignant B cells, the CAR activates T-cell cytotoxicity, cytokine release, proliferation, and persistence to eliminate CD19-positive tumor cells; product uses a defined CD4/CD8 composition.
YES
DIRECT
Anti-CD19 CAR T cells recognize CD19 on target cells, form an immunologic synapse, and kill via perforin/granzyme cytolysis and death receptor pathways (e.g., Fas–FasL), with supportive cytokine-mediated apoptosis.
Bispecific T-cell engager (BiTE) antibody that links CD3 on T cells to CD19 on B-lineage ALL blasts, redirecting T-cell cytotoxicity and inducing cytokine release; given by continuous infusion.
Single-chain bispecific antibody (BiTE) that binds CD3 on T cells and CD19 on B-lineage cells, physically bringing them together to form an immunologic synapse and redirect T-cell cytotoxicity (perforin/granzyme) against CD19+ blasts, with associated cytokine release; active independent of MHC.
YES
DIRECT
Blinatumomab links CD3 on T cells to CD19 on target cells, forming an immunologic synapse and inducing T cell perforin/granzyme-mediated killing (MHC-independent).